MX367268B - Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. - Google Patents

Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.

Info

Publication number
MX367268B
MX367268B MX2015015758A MX2015015758A MX367268B MX 367268 B MX367268 B MX 367268B MX 2015015758 A MX2015015758 A MX 2015015758A MX 2015015758 A MX2015015758 A MX 2015015758A MX 367268 B MX367268 B MX 367268B
Authority
MX
Mexico
Prior art keywords
vaccine compositions
antigen
immunostimulatory oligonucleotides
novel vaccine
component
Prior art date
Application number
MX2015015758A
Other languages
English (en)
Other versions
MX2015015758A (es
Inventor
Paul Joseph Dominowski
Richard Lee Krebs
Sharath K Rai
Laurel Mary Sly
Corey Patrick Cook
Duncan Mwangi
Dennis L Foss
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2015015758A publication Critical patent/MX2015015758A/es
Publication of MX367268B publication Critical patent/MX367268B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición de vacuna que comprende un componente de antígeno y un componente de adyuvante, en la que el componente de adyuvante comprende un oligonucleótido inmunoestimulante de clase P y o bien una combinación de una saponina y un esterol; o una fase oleosa que comprende un aceite y, opcionalmente, uno o más emulsionantes, comprendiendo dicha fase oleosa el 2-20 % v / v de la composición de vacuna, en la que dicho componente de antígeno es un antígeno del EHV o un antígeno de Leishmania.
MX2015015758A 2013-05-14 2014-05-12 Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. MX367268B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361823189P 2013-05-14 2013-05-14
PCT/US2014/037705 WO2014186291A1 (en) 2013-05-14 2014-05-12 Novel vaccine compositions comprising immunostimulatory oligonucleotides

Publications (2)

Publication Number Publication Date
MX2015015758A MX2015015758A (es) 2016-03-16
MX367268B true MX367268B (es) 2019-08-12

Family

ID=50897961

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015015758A MX367268B (es) 2013-05-14 2014-05-12 Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.
MX2019009407A MX2019009407A (es) 2013-05-14 2015-11-13 Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019009407A MX2019009407A (es) 2013-05-14 2015-11-13 Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.

Country Status (20)

Country Link
EP (2) EP3542819B1 (es)
JP (2) JP6505084B2 (es)
CN (2) CN105263518B (es)
AR (1) AR096277A1 (es)
AU (2) AU2014265649B2 (es)
BR (1) BR112015028748A2 (es)
CA (2) CA2911938C (es)
DK (1) DK3542819T3 (es)
ES (2) ES2894138T3 (es)
HK (1) HK1219426A1 (es)
HR (1) HRP20211452T1 (es)
HU (1) HUE056040T2 (es)
LT (1) LT3542819T (es)
MX (2) MX367268B (es)
PL (1) PL3542819T3 (es)
PT (2) PT2996719T (es)
RU (1) RU2627447C2 (es)
SI (1) SI3542819T1 (es)
WO (1) WO2014186291A1 (es)
ZA (1) ZA201507774B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6975132B2 (ja) * 2015-07-20 2021-12-01 ゾエティス・サービシーズ・エルエルシー リポソームアジュバント組成物
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
BE1023538B1 (fr) * 2016-04-22 2017-04-26 Sil'innov Scrl Silices mésoporeuses et leur procédé de synthèse
TW202206098A (zh) * 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7904021A (nl) * 1979-05-22 1980-04-29 Gist Brocades Nv Gecombineerd vaccin en werkwijze voor het bereiden van dit gecombineerd vaccin tegen door adeno achtige virussen veroorzaakte eiproduktiedalingen en door reo virus veroorzaakte ziekteverschijnselen.
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
MXPA04000680A (es) * 2001-07-27 2004-04-05 Wyeth Corp Vacuna para virus west nile.
CN1678188B (zh) * 2002-07-03 2012-10-10 科勒制药集团有限公司 调节免疫反应的核酸成份
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
KR101251707B1 (ko) * 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
CA2664619C (en) * 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
JP2011251963A (ja) * 2010-05-28 2011-12-15 Coley Pharmaceutical Group Inc 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
WO2012064659A1 (en) * 2010-11-08 2012-05-18 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis

Also Published As

Publication number Publication date
CA2911938C (en) 2019-07-16
CN105263518B (zh) 2018-03-20
HK1219426A1 (zh) 2017-04-07
HRP20211452T1 (hr) 2021-12-24
CN105263518A (zh) 2016-01-20
AU2014265649A1 (en) 2015-11-12
RU2015146752A (ru) 2017-06-20
ES2742325T3 (es) 2020-02-13
ES2894138T3 (es) 2022-02-11
MX2015015758A (es) 2016-03-16
PL3542819T3 (pl) 2022-01-10
EP3542819B1 (en) 2021-08-18
SI3542819T1 (sl) 2021-11-30
AU2017232231A1 (en) 2017-10-12
MX2019009407A (es) 2019-09-26
CA2911938A1 (en) 2014-11-20
JP2019108328A (ja) 2019-07-04
LT3542819T (lt) 2021-11-10
BR112015028748A2 (pt) 2017-09-19
CA3027289A1 (en) 2014-11-20
DK3542819T3 (da) 2021-09-20
AU2014265649B2 (en) 2017-10-19
RU2627447C2 (ru) 2017-08-08
WO2014186291A1 (en) 2014-11-20
EP2996719B1 (en) 2019-06-26
CN108079290A (zh) 2018-05-29
HUE056040T2 (hu) 2022-01-28
EP3542819A1 (en) 2019-09-25
PT3542819T (pt) 2021-10-14
NZ713360A (en) 2021-06-25
JP2016518446A (ja) 2016-06-23
PT2996719T (pt) 2019-09-03
AR096277A1 (es) 2015-12-16
JP6505084B2 (ja) 2019-04-24
EP2996719A1 (en) 2016-03-23
ZA201507774B (en) 2017-09-27

Similar Documents

Publication Publication Date Title
ZA201903620B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
HUS2200035I1 (hu) Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik
EP2762155A3 (en) Vaccine Composition
MX2023012979A (es) Procedimiento para fabricar un adyuvante.
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
MX2019004690A (es) Constructos de anticuerpos.
MX2019009407A (es) Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.
EP3669891A4 (en) VACCINE ADJUVANS WITH LIPOPEPTIDE-INSERTED LIPOSOME AS THE ACTIVE SUBSTANCE AND USE OF IT
PH12019501569A1 (en) Universal influenza vaccine compositions
IL276661A (en) Immunogenic preparation containing staphylococcal antigens
MX2021000951A (es) Composición que contiene vacuna contra la influenza.
IN2014CN03454A (es)
EP3730620A4 (en) CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION
WO2018138681A9 (en) Hemagglutinin-specific antibodies and uses thereof
BR112016016672A2 (pt) Uso de uma composição
RS62793B1 (sr) Heterobasidion annosum ekstrakt protiv kancera, kompozicije i njihova primena
MX2021009718A (es) Composicion de adyuvante para una vacuna.
EP3710051A4 (en) Vaccine compositions
PH12018500146A1 (en) Liposomal adjuvant compositions
EP3585885A4 (en) INFLUENZA IMMUNOGENIC COMPOSITIONS
IN2014DE00010A (es)

Legal Events

Date Code Title Description
FG Grant or registration